Bayer AG and Onyx Pharmaceuticals Inc. said on Wednesday that it asked U.S. regulators to approve their Nexavar drug as a treatment for liver cancer.

Nexavar, which is already approved for kidney cancer, earlier this month showed in a study that it could extend the life of patients with advanced liver cancer, adding about three months of survival compared with a placebo.

(Reporting by Lewis Krauskopf)